Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
109results about How to "Increased apoptosis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Caspase-9 : BIR domain of XIAP complexes and methods of use
InactiveUS20040180828A1Avoid possibilityIncreased apoptosisPowder deliveryElectrotherapyApoptosisCaspase-9
The present invention provides polypeptides and specific binding agents that modify the activity of an initiator caspase involved in apoptosis, caspase-9. The polypeptides include the third baculoviral IAP repeat (BIR3) of an IAP and form a heterodimer complex with caspase-9. Nucleic acid molecules including expression vectors encoding the polypeptides and variants thereof as well as variants of caspase-9 are provided. Such polypeptide and nucleic acid molecules may be used for modifying apoptosis.
Owner:THE TRUSTEES FOR PRINCETON UNIV
Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
InactiveUS20060094674A1Reduce spreadIncreased apoptosisBiocideGenetic material ingredientsMEK inhibitorTyrosine-kinase inhibitor
The invention features methods and compositions including an mTOR inhibitor and a tyrosine kinase inhibitor for reducing the proliferation of and enhancing the apoptosis of neoplastic cells. The addition of an MEK inhibitor to this combination further enhances the effectiveness of this therapeutic method.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC
Bcr-abl truncation mutations
ActiveUS20110072889A1Good effectReduced growth rateMicrobiological testing/measurementFlow propertiesGene productTyrosine-kinase inhibitor
Truncation variants of BCR-ABL mRNA that produces BCR-ABL proteins with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is described. Vectors for expressing the truncated gene products are described as well as recombinant cells that express the truncated gene products from cDNA constructs. Also provided are methods compositions and kits for detecting the BCR-ABL truncation variants. Also provided are methods for determining the prognosis of a patient diagnosed as having myeloproliferative disease, and methods for predicting the likelihood for resistance to a treatment with tyrosine kinase inhibitor in a patient diagnosed as having myeloproliferative disease. Additionally, methods for screening BCR-ABL tyrosine kinase domain inhibitors which rely on the recombinant cells are also disclosed.
Owner:QUEST DIAGNOSTICS INVESTMENTS INC
Anti-il-6 antibodies for the treatment of anemia
ActiveUS20120128626A1Inhibition effectInhibitionBiocidePeptide/protein ingredientsCvd riskHead and neck cancer
The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat anemia (e.g., anemia associated with chemotherapy) including persons on a treatment regimen with a drug or chemotherapy and / or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of anemia.
Owner:ALDERBIO HLDG LLC +1
Novel tricyclic protein kinase modulators
InactiveUS20110071136A1Good treatment effectReduce cell proliferationBiocideSenses disorderInflammationImmunologic disease
The invention provides compounds that inhibit CK2 and / or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders.
Owner:SENHWA BIOSCIENCES INC
Prevention of ovarian cancer by administration of progestin products
InactiveUS6977250B2High activityEliminate side effectsOrganic active ingredientsBiocideProgestin therapyEpithelial ovarian cancer
The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering progestin products, either alone or in combination with other agents such as estrogen products.
Owner:NEW LIFE PHARMA
Death domain containing receptor 4
InactiveUS20040136950A1Increased apoptosisEnhanced signalVirusesPeptide/protein ingredientsAntibodyDisease
The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and / or antagonists of DR4 activity.
Owner:THE RGT OF THE UNIV OF MICHIGAN +1
Anti-il-6 antibodies for the treatment of oral mucositis
ActiveUS20120189629A1InhibitionEasy to keepOrganic active ingredientsPeptide/protein ingredientsIncreased riskCvd risk
Owner:VITAERIS INC +1
Melanoma chemoprevention
ActiveUS9393225B2Inhibits melanoma cell growthLowered STAT expressionPharmaceutical delivery mechanismDisease diagnosisEnteral administrationMedicine
Disclosed herein are methods and uses for preventing melanoma, reducing progression of atypical nevi, and inducing cell cycle arrest and / or apoptosis in a melanoma cell through oral and enteral administration of sulforaphane to subjects indicated to be at risk due to factor(s) such as medical history of atypical nevi, melanoma, or UV exposure. Sulforaphane can be administered orally as a safe and well-tolerated natural agent as a chemopreventive strategy in individuals with atypical melanocytic nevi.
Owner:UNIVERSITY OF PITTSBURGH
Binding Polypeptides and Uses Thereof
ActiveUS20070202552A1Small sizeHigh-quality target binding characteristicAntipyreticAnalgesicsHeterologousAntigen Binding Fragment
The invention provides antibodies or antigen binding fragments thereof to DR5 and HER-2. The antibodies and / or antigen binding fragments thereof comprise variant CDRs comprising highly restricted amino acid sequence diversity. The invention also provides these polypeptides as fusion polypeptides to heterologous polypeptides such as at least a portion of phage or viral coat proteins, tags and linkers. In addition, compositions and methods of use for treatment of cancer and immune related conditions are provided.
Owner:GENENTECH INC
Anti-Tumor Activity of an Oncolytic Adenovirus-Delivered Oncogene siRNA
InactiveUS20070258952A1Minimizing potential cytotoxicityIncrease infectivityBiocideSpecial deliveryOncolytic adenovirusOncogene MYC
The present invention includes compositions and methods for the knockdown of one or more genes to a target cell in need of gene therapy by using an siRNA transgene that is integrated into a replication-competent, oncolytic adenovirus.
Owner:GRADALIS +2
HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma
PendingUS20150105383A1Increased apoptosisReduce proliferationBiocideOrganic chemistryHDAC inhibitorCancer research
The invention relates to HDAC inhibitors, or combinations comprising an HDAC inhibitor and a PI3K inhibitor for the treatment of non-hodgkin's lymphoma in a subject in need thereof. Also provided herein are methods for treating non-hodgkin's lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a PI3K inhibitor.
Owner:ACETYLON PHARMA
Plasma modified medical devices and methods
InactiveUS20130046375A1Increased apoptosisGood biocompatibilitySurgical adhesivesPharmaceutical delivery mechanismActive agentThrombus
Coatings, devices and methods are provided, wherein the contacting surface of a medical device with at least one contacting surface for contacting a bodily fluid or tissue, wherein long-lasting and durable bioactive agents or functional groups are deposited on the contacting surface through a unique two-step plasma coating process with deposition of a thin layer of plasma coating using a silicon-containing monomer in the first step and plasma surface modification using a mixture of nitrogen-containing molecules and oxygen-containing molecules in the second step. The two-step plasma coating process enables the implantable medical device to prevent both restenosis and thrombosis under clinical conditions. The invention also relates to surface treatment of metallic and polymeric biomaterials used for making of medical devices with significantly improved clinical performance and durability.
Owner:CHEN MENG
Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
ActiveUS20110152240A1Good treatment effectIncreased apoptosisBiocideNervous disorderDiseaseCancer research
The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and have the following general formula:
Owner:SENHWA BIOSCIENCES INC
Tumor necrosis factor receptor 5
InactiveUS20010021516A1Reduce capacityIncreased apoptosisBacteriaPeptide/protein ingredientsTRAIL ReceptorsAgonist
The present invention relates to a novel human gene encoding a polypeptide which is a member of the TNF receptor family, and has now been found to bind TRAIL. More specifically, an isolated nucleic acid molecule is provided encoding a human polypeptide named tumor necrosis factor receptor-5, sometimes referred to as "TNFR-5" or "TR5," and now referred to hereinafter as "TRAIL receptor without intracellular domain" or "TRID." TRID polypeptides are also provided, as are vectors, host cells, and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists or antagonists of TRAIL polypeptide activity. Also provided are diagnostic and therapeutic methods utilizing such compositions.
Owner:HUMAN GENOME SCI INC
Nucleic acids encoding tumor necrosis factor receptor 5
InactiveUS6261801B1Reduce capacityIncreased apoptosisBacteriaPeptide/protein ingredientsLine of therapyNucleic acid molecule
The present invention relates to a novel human gene encoding a polypeptide which is a member of the TNF receptor family, and has now been found to bind TRAIL. More specifically, an isolated nucleic acid molecule is provided encoding a human polypeptide named tumor necrosis factor receptor-5, sometimes referred to as "TNFR-5" or "TR5", and now referred to hereinafter as "TRAIL receptor without intracellular domain" or "TRID." TRID polypeptides are also provided, as are vectors, host cells, and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists or antagonists of TRAIL polypeptide activity. Also provided are diagnostic and therapeutic methods utilizing such compositions.
Owner:HUMAN GENOME SCI INC
Rhodanines and related heterocycles as kinase inhibitors
InactiveUS20100331315A1Good treatment effectIncreased apoptosisBiocideOrganic chemistryImmunologic disordersMedicine
The invention provides compounds that inhibit PIM kinases and / or CK2, and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, vascular disorders, pathogenic infections and certain immunological disorders.
Owner:SENHWA BIOSCIENCES INC
Combination therapy of cancer with Anti-endoglin antibodies and Anti-vegf agents
InactiveUS20120244147A1Improve the situationImprove survivalSenses disorderAntipyreticEndoglinBevacizumab Injection
The present application relates to compositions of chimeric anti-endoglin antibodies and anti-VEGF agents. Another aspect relates to the use of chimeric anti-endoglin antibodies and Bevacizumab. Another aspect relates to the use of the compositions to inhibit VEGF induced sprouting. Another aspect relates to the use of the compositions to inhibit angiogenesis.
Owner:HEALTH RES INC +1
Compositions and methods for selecting a treatment for b-cell neoplasias
InactiveUS20160282354A1Reduce cell proliferationHigh expressionMicrobiological testing/measurementBiological material analysisPathology
The present invention features compositions and methods for identifying a subject having a B cell neoplasia or related condition responsive to treatment with lenalidomide and lenalidoinide-related compounds.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
Denatured collagen peptides and uses thereof
InactiveUS20080008707A1Relieve symptomsShrink tumorConnective tissue peptidesImmunoglobulins against animals/humansAbnormal tissue growthCell-Extracellular Matrix
The invention provides peptide antagonists, such as synthetic collagen peptides. The invention provides antibody antagonists, or functional fragments thereof, that preferentially bind to denatured extracellular matrix components. It additionally provides methods for using the antagonists for inhibiting angiogenesis, tumor metastasis, and other tumor developmental processes, including cell migration, cell adhesion, cell proliferation, and tumor growth and for treating angiogenesis-dependent conditions or collagen-dependent conditions. The application also provides for use of the antagonists as a vaccine for inducing an immune response, immune focusing and induction of antibody responses.
Owner:CELL MATRIX
Survivin-derived peptides and use thereof
ActiveUS20040176573A1Easy to filterIncrease the immuogenicity of survivin-derived peptidesPeptide/protein ingredientsApoptosis related proteinsMHC class IWilms' tumor
MHC Class I-restricted peptides derived from the tumor associated antigen, survivin, which peptides are capable of binding to Class I HLA molecules at a high affinity, capable of eliciting INF-gamma-producing cells in a PBL population of a cancer patient and capable of in situ detection of cytotoxic T cells in a tumor tissue, therapeutic and diagnostic composition comprising the peptide and uses hereof.
Owner:SURVAC
Methods and compositions for specific modulation of MCL-1
ActiveUS9079970B2Regulating MCL-1 activityApoptosis is enhancedAntibacterial agentsOrganic active ingredientsDiseasePharmacometrics
Owner:DANA FARBER CANCER INST INC
Vdac1 compositions and methods of use thereof for regulating apoptosis
ActiveUS20120214741A1Good effectIncreased apoptosisCompound screeningApoptosis detectionDiseaseNucleotide
The present invention relates generally to the mitochondrial protein, voltage-dependent anion channel (VDAC), polynucleotides encoding same and variants thereof, as well as peptide fragments, peptide derivatives and analogs. In particular, the present invention is directed to VDAC1 and specific amino acid and polynucleotide sequences thereof useful in inducing or regulating apoptosis and to pharmaceutical compositions comprising same useful in the treatment of diseases associated with aberrant apoptosis.
Owner:BEN GURION UNIVERSITY OF THE NEGEV
Interventions to mimic the effects of calorie restriction
InactiveUS20030124540A1Affecting responseLess in CRBioreactor/fermenter combinationsBiological substance pretreatmentsCaloric restrictionsIntervention measures
Long term calorie restriction has the benefit of increasing life span. Methods to screen interventions that mimic the effects of calorie restriction are disclosed. Extensive analysis of genes for which expression is statistically different between control and calorie restricted animals has demonstrated that specific genes are preferentially expressed during calorie restriction. Screening for interventions which produce the same expression profile will provide interventions that increase life span. In a further aspect, it has been discovered that test animals on a calorie restricted diet for a relatively short time have a similar gene expression profile to test animals which have been on a long term calorie restricted diet.
Owner:RGT UNIV OF CALIFORNIA
Survivin
InactiveUS20060160095A1Inhibitory effectDecreased expression of geneGenetic material ingredientsMicrobiological testing/measurementRegulator geneGiant Neutrophils
The invention provides a method for detecting apoptosis in a myeloid cell comprising detecting an alteration in any one of: i) a Survivin polypeptide having an amino acid sequence as set out in SEQ ID NO: 1; ii) a polypeptide having at least 80% homology with i); iii) a nucleic acid encoding a polypeptide having the sequence set out in i) or ii); iv) a nucleic acid which hybridises under stringent conditions to the sequence set out in iii); or v) the complement of iii) or iv). The invention accordingly provides a method of modulating apoptosis in neutrophils by modulating Survivin gene expression and a method of treating inflammatory disease by modulating Survivin gene expression or function.
Owner:EIRX THERAPEUTICS +2
Bcr-abl variants
ActiveUS20100113470A1Reduced growth rateReduced viabilityBiocideOrganic active ingredientsBcr abl kinaseGene product
A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct. Also provided are methods compositions and kits for detecting the BCR-ABL splice variant. Additionally, methods for screening BCR-ABL kinase domain inhibitors which rely on the recombinant cells and methods of predicting likelihood for resistance of a CML patient with a BCR / ABL translocation respond to treatment with one or more BCR-ABL kinase inhibitors are also disclosed.
Owner:QUEST DIAGNOSTICS INVESTMENTS INC
Prevention of ovarian cancer by administration of agents that induce biologic responses
InactiveUS20070213543A1Avoid developmentReduce riskOrganic active ingredientsOrganic chemistryEpitheliumOncology
The present invention relates to compositions and methods for preventing the development of epithelial ovarian cancer by administering compounds in an amount capable of regulating TGF-β expression in the ovarian epithelium and / or capable of optimally altering expression of other surrogate biomarkers identified by microarray technology. HRT and OCP regimens comprising such compositions and methods are disclosed.
Owner:RODRIGUEZ GUSTAVO C
Voltage dependent anion channel (VDAC1) compositions and methods of use thereof for regulating apoptosis
Owner:BEN GURION UNIVERSITY OF THE NEGEV
VDAC1 compositions and methods of use thereof for regulating apoptosis
Owner:BEN GURION UNIVERSITY OF THE NEGEV
Methods of treating ischemia
The invention provides compositions comprising stem and / or progenitor cells that have been treated to enhance the therapeutic properties of the cells for treating ischemia. In particular, the present invention relates to the use of stem and / or progenitor cells having enhanced therapeutic properties to treat an ischemic tissue, a tissue damaged by ischemia, or at least one symptom associated with an ischemic tissue or a tissue damaged by ischemia.
Owner:FATE THERAPEUTICS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com